2,5,7-trimethylimidazo[1,2-c]pyrimidine | 1179357-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2,5,7-trimethylimidazo[1,2-c]pyrimidine
• CAS: 1179357-81-3
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: UTUSGZNWFYECBF-UHFFFAOYSA-N

物化性质

• 熔点：
  125-126 °C
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 1-(4-甲氧基苯基)哌嗪 、 2,5,7-trimethylimidazo[1,2-c]pyrimidine 在 溶剂黄146 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 12.0h， 以40%的产率得到3-{[4-(4-methoxyphenyl)piperazin-1-yl]methyl}2,5,7-trimethylimidazo[1,2-c]pyrimidine
  参考文献：
  名称：

  新的N-杂芳族5/6环曼尼希碱基的设计，合成及多巴胺D4受体结合活性

  摘要：

  一系列苯基哌嗪甲基取代的1 H-吡咯并[2,3- c ]吡啶，咪唑并[1,2- c ]-，吡咯并[2,3- d ]-和吡咯并[3,2- d ]嘧啶制备为选择性多巴胺D4-配体。吡咯并[2,3- d ]嘧啶衍生物12D（ķ我 =  1,9 1nM）和34D（ķ我 =  2,4纳米）以及吡咯并[3,2- d ]嘧啶曼尼希碱49F（ķ我 = 2,8 nM）显示出高多巴胺D4受体活性，优于非典型抗精神病药氯氮平。

  DOI：

  10.1016/j.bmc.2009.05.015
• 作为产物：
  描述：

  4-氨基-2,6-二甲基嘧啶 、 一氯丙酮 以 正丁醇 为溶剂， 反应 3.0h， 以45%的产率得到2,5,7-trimethylimidazo[1,2-c]pyrimidine
  参考文献：
  名称：

  新的N-杂芳族5/6环曼尼希碱基的设计，合成及多巴胺D4受体结合活性

  摘要：

  一系列苯基哌嗪甲基取代的1 H-吡咯并[2,3- c ]吡啶，咪唑并[1,2- c ]-，吡咯并[2,3- d ]-和吡咯并[3,2- d ]嘧啶制备为选择性多巴胺D4-配体。吡咯并[2,3- d ]嘧啶衍生物12D（ķ我 =  1,9 1nM）和34D（ķ我 =  2,4纳米）以及吡咯并[3,2- d ]嘧啶曼尼希碱49F（ķ我 = 2,8 nM）显示出高多巴胺D4受体活性，优于非典型抗精神病药氯氮平。

  DOI：

  10.1016/j.bmc.2009.05.015

文献信息

• PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
  申请人：REBORNA BIOSCIENCES, INC.

  公开号：US20220287748A1

  公开（公告）日：2022-09-15

  A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by the formula (I) or a salt thereof: wherein: W 1 , W 2 , and W 3 are each independently selected from the group consisting of C—R 2 , C—R 3 , C—R c , and C—R d , and are defined by one of the followings (i) to (iv): (i) when W 3 is C—R 2 , then W 1 is C—R 3 , W 2 is C—R c or N, and R 1 is a hydrogen atom; (ii) when W 3 is C—R 3 , then W 1 is C—R 2 , W 2 is C—R c or N, and R 1 is a hydrogen atom, C 1-8 alkyl, or C 1-8 alkoxy; (iii) when W 1 is C—R 2 , then W 2 is C—R c or N, W 3 is C—R d , and R 1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; and (iv) when W 2 is C—R 2 , W 1 is C—R c , W 3 is C—R d , and R 1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; R 2 is a 6- or more membered aromatic ring optionally substituted with a non-aromatic substituent; R 3 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; Q 1 is selected from C—R a and N; Q 2 is selected from C—R b and N; and R a , R b , R c , and R d are each independently selected from the group consisting of a hydrogen atom, halogen, C 1-8 alkyl, C 1-8 alkoxy, and a cyano group.
• Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5/6-ring Mannich bases
  作者：Sabine Linz、Jörg Müller、Harald Hübner、Peter Gmeiner、Reinhard Troschütz

  DOI：10.1016/j.bmc.2009.05.015

  日期：2009.7

  A series of phenylpiperazine-methyl-substituted 1H-pyrrolo[2,3-c]pyridine, imidazo[1,2-c]-, pyrrolo[2,3-d]- and pyrrolo[3,2-d]pyrimidines were prepared as selective dopamine D4-ligands. The pyrrolo[2,3-d]pyrimidine derivatives 12d (Ki = 1,9 nM) and 34d (Ki = 2,4 nM) as well as the pyrrolo[3,2-d]pyrimidine Mannich base 49f (Ki = 2,8 nM) showed high dopamine D4 receptor activity superior to the atypical

  一系列苯基哌嗪甲基取代的1 H-吡咯并[2,3- c ]吡啶，咪唑并[1,2- c ]-，吡咯并[2,3- d ]-和吡咯并[3,2- d ]嘧啶制备为选择性多巴胺D4-配体。吡咯并[2,3- d ]嘧啶衍生物12D（ķ我 =  1,9 1nM）和34D（ķ我 =  2,4纳米）以及吡咯并[3,2- d ]嘧啶曼尼希碱49F（ķ我 = 2,8 nM）显示出高多巴胺D4受体活性，优于非典型抗精神病药氯氮平。